Literature DB >> 20668444

Clinically significant CYP2C inhibition by noscapine but not by glucosamine.

S Rosenborg1, M Stenberg, S Otto, J Ostervall, M Masquelier, Q-Y Yue, L Bertilsson, E Eliasson.   

Abstract

Noscapine and glucosamine reportedly interact with warfarin. We investigated the effects of these drugs on various cytochrome P450 (CYP) activity markers. Twelve healthy subjects were phenotyped at baseline and during separate treatments with noscapine and glucosamine. Whereas glucosamine had no significant effect on CYP activity, noscapine caused marked inhibition of CYP2C9 (4.9-fold increase in urinary losartan/E3174 ratio) and CYP2C19 (3.6-fold increase in the plasma omeprazole/5-hydroxyomeprazole ratio). Noscapine-dependent inhibition of CYP2C9 may explain the interaction with warfarin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20668444     DOI: 10.1038/clpt.2010.107

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Combination therapy for cerebral ischemia: do progesterone and noscapine provide better neuroprotection than either alone in the treatment?

Authors:  Manisha Kawadkar; Avinash S Mandloi; Nidhi Singh; Rajesh Mukharjee; Vipin V Dhote
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-01-06       Impact factor: 3.000

2.  A practical strategy to develop isoform-selective near-infrared fluorescent probes for human cytochrome P450 enzymes.

Authors:  Lei Feng; Xiangge Tian; Dahong Yao; Zhenlong Yu; Xiaokui Huo; Zhenhao Tian; Jing Ning; Jingnan Cui; Tony D James; Xiaochi Ma
Journal:  Acta Pharm Sin B       Date:  2021-11-25       Impact factor: 14.903

3.  Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.

Authors:  Nan Zhang; Ryan P Seguin; Kent L Kunze; Yan-Yan Zhang; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2013-09-17       Impact factor: 3.922

4.  No changes of cholesterol levels with a commercially available glucosamine product in patients treated with lipid lowering drugs: a controlled, randomised, open cross-over trial.

Authors:  Robert Eggertsen; Ake Andreasson; Lennart Andrén
Journal:  BMC Pharmacol Toxicol       Date:  2012-10-10       Impact factor: 2.483

5.  Xenobiotic exposure and autoimmune hepatitis.

Authors:  Kathleen M Gilbert
Journal:  Hepat Res Treat       Date:  2010-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.